ABT-510

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameABT-510
Drug Alias NameABT-510
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionAngiogenesis inhibitorsApoptosis inducers
TargetsNot applicable
Therapy Area/IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbbott LaboratoriesNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsN/A
Inactive IndicationsSkin MelanomaSolid tumoursCarcinoma, Non-Small-Cell Lung +[9] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank